Nyrada, Inc. · ASX:NYR
Nyrada — ShareCafe Small Cap 'Hidden Gems' Webinar (September 2020)
12 slides from Nyrada's conference presentation, Sep 11, 2020
Slide 1: Corporate Presentation for ShareCafe 'Hidden Gems' Webinar
For personal use only 11 September 2020 Sydney, Australia Corporate Presentation for ShareCafe ‘Hidden Gems’ Webinar Sydney, 11 September 2020 Nyrada Inc. (ASX:NYR) provides to shareholders and the market generally the corporate presentation for the ShareCafé Small Cap “Hidden Gems” webinar series t
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope New Therapies for Cardiovascular & Neurological Diseases Investor Update September 2020
Slide 4: Nyrada Programs & Strategy
Nyrada Programs & Strategy For personal use only Drug discoverer Cholesterol lowering drug and early stage Small molecule PCSK9 inhibitor to help developer people reach their target LDL cholesterol level Brain injury drug To help people who sustain a traumatic brain injury (TBI) or suffer a stroke I
Slide 5: Problem – High LDL Cholesterol
Problem – High LDL Cholesterol For personal use only High LDL Cholesterol leading cause of cardiovascular disease Cardiovascular disease responsible for 1 in 4 deaths 62.6 million US adults with elevated LDL-C 3
Slide 6: Statin Drugs
Statin Drugs For personal use only 19.4 million 27.4 million Unable to achieve US adults with elevated LDL-C target despite LDL-C are taking a statin taking statin therapy Low cost Suboptimal efficacy Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin e
Slide 7: Current PCSK9 Inhibitors
Current PCSK9 Inhibitors For personal use only Binds to PCSK9 protein Effective, combined with statin Blocks action of PCSK9 on cholesterol receptor Expensive US$5,800 per year Inconvenient (2-4 weekly injection) Statin + current PCSK9 inhibitor = expensive and inconvenient 5
Slide 8: What is Unique?
What is Unique? For personal use only Oral PCSK9 Convenient Cost- treatment for patient effective Small molecule PCSK9 inhibitor overcomes longstanding challenge of an oral treatment Can be combined with statin to deliver a first ever single pill PCSK9/statin treatment 6
Slide 9: Brain Injury Problem
Brain Injury Problem For personal use only Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ongoing healthcare (Suitable for l
Slide 10: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 11: Program Status & Recent Achievements
Program Status & Recent Achievements For personal use only First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering Drug: late-2021 - Brain Injury Drug: mid-2022 Nyrada NYX-PCSK9i shows equivalency to Repatha® and Praluent® in human white b
Slide 12: Discover More & Follow Us
Discover More & Follow Us For personal use only www.nyrada.com @nyrada_inc @nyrada_inc Neuroprotection Animation Cholesterol-Lowering Animation ASX: NYR 10
Nyrada — ShareCafe Small Cap 'Hidden Gems' Webinar (September 2020) on 6ix